The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men
Abstract
To compare the efficacy of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer, we conducted a prospective clinical trial at 6 university centers of 6,630 male volunteers 50 years old or older who underwent PSA determination (Hybritech Tandem-E or Tandem-R assays) and digital rectal examination. Quadrant biopsies were performed if the PSA level was greater than 4 micrograms/l or digital rectal examination was suspicious, even if transrectal ultrasonography revealed no areas suspicious for cancer. The results showed that 15% of the men had a PSA level of greater than 4 micrograms/l, 15% had a suspicious digital rectal examination and 26% had suspicious findings on either or both tests. Of 1,167 biopsies performed cancer was detected in 264. PSA detected significantly more tumors (82%, 216 of 264 cancers) than digital rectal examination (55%, 146 of 264, p = 0.001). The cancer detection rate was 3.2% for digital rectal examination, 4.6% for PSA and 5.8% for the 2 methods combined. Positive predictive value was 32% for PSA and 21% for digital rectal examination. Of 160 patients who underwent radical prostatectomy and pathological staging 114 (71%) had organ confined cancer: PSA detected 85 (75%) and digital rectal examination detected 64 (56%, p = 0.003). Use of the 2 methods in combination increased detection of organ confined disease by 78% (50 of 64 cases) over digital rectal examination alone. If the performance of a biopsy would have required suspicious transrectal ultrasonography findings, nearly 40% of the tumors would have been missed. We conclude that the use of PSA in conjunction with digital rectal examination enhances early prostate cancer detection. Prostatic biopsy should be considered if either the PSA level is greater than 4 micrograms/l or digital rectal examination is suspicious for cancer, even in the absence of abnormal transrectal ultrasonography findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171501 · Cited by 2,451
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Self-citationA Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
Catalona, W. J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080052031 · Cited by 998
Self-citationStamey, T. A., Kabalin, J. N., Mcneal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A., & Yang, N. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)41175-x · Cited by 871
Cooner, W. H., Mosley, B. R., Rutherford, C. L., Beard, J. H., Pond, H. S., Terry, W. J., Igel, T. C., & Kidd, D. D. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)40211-4 · Cited by 767
Family history and the risk of prostate cancer
Steinberg, G. D., Carter, B. S., Beaty, T. H., Childs, B., & Walsh, P. C. (1990) · The Prostate · doi:10.1002/pros.2990170409 · Cited by 718
Screening for Prostatic Carcinoma with Prostate Specific Antigen
Brawer, M. K., CHETNER, M. P., Beatie, J., Büchner, D. M., Vessella, R. L., & Lange, P. H. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37401-3 · Cited by 612
Nerve-Sparing Radical Prostatectomy: Evaluation of Results after 250 Patients
Catalona, W. J., & Bigg, S. W. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)40013-9 · Cited by 391
Self-citationMcNeal, J. E. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90106-d · Cited by 300
Early detection of prostate cancer
Scardino, P. T., Weaver, R., & Hudson, M. A. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90102-9 · Cited by 288
Self-citationRichie, J. P., Catalona, W. J., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., et al. (1993) · Urology · doi:10.1016/0090-4295(93)90359-i · Cited by 230
Self-citationThe logistic modeling of sensitivity, specificity, and predictive value of a diagnostic test
Coughlin, S. S., Trock, B., Criqui, M. H., Pickle, L. W., Browner, D., & Tefft, M. C. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90180-u · Cited by 167
A decision analysis of alternative treatment strategies for clinically localized prostate cancer
Fleming, C. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500200064035 · Cited by 4
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
International Variation in Prostate Cancer Incidence and Mortality Rates
Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.054 · Cited by 1,521
Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., et al. (1998) · JAMA · doi:10.1001/jama.279.19.1542 · Cited by 1,162
Self-citationSturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
AUA PRACTICE GUIDELINES COMMITTEE (2003) · Journal of Urology · doi:10.1097/01.ju.0000078083.38675.79 · Cited by 844
Metadata
- Authors
- Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., Macfarlane, M. T., & Southwick, P. C.
- Venue
- Journal of Urology
- Published
- 1994-05
- Volume
- 151
- Issue
- 5
- Pages
- 1283-1290
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2209826608
- Cited by
- 1,592
- References
- 15
- FWCI
- 85.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.